OTIC Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (11 апр. 2023 @ 22:58):

Stats
Объем за сегодня	1.94M
Средний объем	876 957
Рыночная капитализация	582 482
EPS	$0 ( 2023-11-08 )
Last Dividend	$0.110 ( 2023-04-11 )
Next Dividend	$0 ( N/A )
P/E	-0.142
ATR14	$0.00500 (58.82%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-15	Hogan H Michael Iii	Buy	0
2022-12-30	Weber David Allen	Sell	91 636	Common Stock
2022-12-28	Cayer Paul E	Sell	40 054	Common Stock
2022-11-28	Capps Vickie L	Sell	42 242	Common Stock
2022-06-21	Schroeder Theodore R	Buy	27 500	Stock Option (right to buy)

INSIDER POWER
-33.40
Last 98 transactions
Buy: 7 968 332 \| Sell: 3 029 863

Объем Корреляция

Длинно: 0.68 (moderate)

Кратко: -0.97 (very strong negative)

Signal:(8.549) Possible Trading Opportunity Present (swing)

Otonomy Inc Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Otonomy Inc Корреляция - Валюта/Сырье

-0.10
( neutral )

-0.03
( neutral )

0.00
( neutral )

-0.13
( neutral )

0.00
( neutral )

0.02
( neutral )

Otonomy Inc Финансовые показатели

Annual	2021
Выручка:	$125 000
Валовая прибыль:	$-245 000 (-196.00 %)
EPS:	$-0.810

FY	2021
Выручка:	$125 000
Валовая прибыль:	$-245 000 (-196.00 %)
EPS:	$-0.810

FY	2020
Выручка:	$273 000
Валовая прибыль:	$-915 000 (-335.16 %)
EPS:	$-1.100

FY	2019
Выручка:	$600 000
Валовая прибыль:	$-312 000 (-52.00 %)
EPS:	$-1.450

Financial Reports:

No articles found.

Otonomy Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.110 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Otonomy Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.110	2023-04-11
Last Dividend	$0.110	2023-04-11
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.110	--
Avg. Dividend % Per Year	39.17%	--
Score	4.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-27)

$0.220 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$0.110	117.50%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-402.60	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.526	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	0.0949	1.500	-0.0565	-0.0848	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	6.52	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.28	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	6.28	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.166	-1.500	7.24	-10.00	[0 - 0.6]
interestCoverageTTM	-31.04	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.669	2.00	-0.223	-0.446	[0 - 30]
freeCashFlowPerShareTTM	-0.673	2.00	-0.337	-0.673	[0 - 20]
debtEquityRatioTTM	-0.0285	-1.500	-0.114	0.171	[0 - 2.5]
grossProfitMarginTTM	-1.960	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-397.00	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-2.68	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00131	0.800	-3.32	-2.66	[0.5 - 2]
Total Score				-3.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.0107	1.000	-0.102	0	[1 - 100]
returnOnEquityTTM	0.0949	2.50	-0.0363	-0.0848	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.673	2.00	-0.224	-0.673	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.669	2.00	-0.223	-0.446	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-339.34	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-1.609

Otonomy Inc

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.